Gilead Sciences is a drug manufacturers-general business based in the US. Gilead Sciences stocks (GILD.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $71.88 – a decrease of 5.52% over the previous week. Gilead Sciences employs 13,600 staff and has a trailing 12-month revenue of around $27.5 billion.
How to buy shares in Gilead Sciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GILD – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Gilead Sciences?
- Has coronavirus impacted Gilead Sciences shares?
- Gilead Sciences shares summary
- Compare share dealing platforms
- Is Gilead Sciences stock a buy or sell?
- Gilead Sciences performance over time
- Is Gilead Sciences suitable for ethical investing?
- Are Gilead Sciences shares over-valued?
- Gilead Sciences's financials
- How volatile are Gilead Sciences shares?
- Does Gilead Sciences pay a dividend?
- Have Gilead Sciences shares ever split?
- Other common questions
Gilead Sciences stock price (NASDAQ:GILD)Use our graph to track the performance of GILD stocks over time.
Gilead Sciences shares at a glance
|Latest market close||$67.81|
|52-week range||$58.88 - $74.12|
|50-day moving average||$70.30|
|200-day moving average||$68.82|
|Wall St. target price||$77.08|
|Dividend yield||$2.81 (3.96%)|
|Earnings per share (TTM)||$5.84|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Gilead Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Gilead Sciences price performance over time
|1 week (2022-01-12)||-6.15%|
|1 month (2021-12-17)||N/A|
|3 months (2021-10-20)||1.42%|
|6 months (2021-07-21)||-0.88%|
|1 year (2021-01-21)||1.24%|
|2 years (2020-01-21)||8.27%|
|3 years (2019-01-18)||69.18|
|5 years (2017-01-20)||71.01|
Is Gilead Sciences under- or over-valued?
Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Gilead Sciences's P/E ratio
Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Gilead Sciences shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gilead Sciences's PEG ratio
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5237. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Gilead Sciences's EBITDA
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14.9 billion.
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.
Gilead Sciences financials
|Revenue TTM||$27.5 billion|
|Operating margin TTM||47.25%|
|Gross profit TTM||$21 billion|
|Return on assets TTM||12.68%|
|Return on equity TTM||37.85%|
|Market capitalisation||$90 billion|
TTM: trailing 12 months
Gilead Sciences's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Gilead Sciences's total ESG risk score
Total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 01/01/2019) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Gilead Sciences's environmental score
Environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Gilead Sciences's social score
Social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Gilead Sciences's governance score
Governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Gilead Sciences's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
Gilead Sciences share dividends
Dividend payout ratio: 32.31% of net profits
Recently Gilead Sciences has paid out, on average, around 32.31% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.96% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 3.96% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.81 per share.
While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that Gilead Sciences may be investing much of the rest of its net profits in future growth.
Gilead Sciences's most recent dividend payout was on 30 December 2021. The latest dividend was paid out to all shareholders who bought their shares by 14 December 2021 (the "ex-dividend date").
Have Gilead Sciences's shares ever split?
Gilead Sciences's shares were split on a 2:1 basis on 28 January 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.
Gilead Sciences share price volatility
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as $58.875 up to $74.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.3619. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
Gilead Sciences overview
Gilead Sciences, Inc. , a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.
Gilead Sciences in the news
Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Chapman Investment Management, LLC Buys Charles Schwab Corp, Tesla Inc, KLA Corp, Sells ...
Members Capital Advisors Inc Buys Vanguard Short-Term Corporate Bond ETF, BTC BlackRock Short ...
Frequently asked questions
More guides on Finder
How to buy Aritzia stock in Canada
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Hifi Finance (MFT) price prediction
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
COVID testing stocks
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
Pendle (PENDLE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Pendle, lists some exchanges where you can get it and provides daily price data on PENDLE.
Hempcoin (THC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.